Profiel
Habil Dorian Bevec was the founder of THERAMetrics holding AG, which was founded in 2001, where he held the title of Chief Science Officer from 2011 to 2012.
He also held the position of Head-Molecular Biology at Axxima Pharmaceuticals AG and Sandoz Research Institute.
Additionally, he was the Chief Development Officer at RELIEF THERAPEUTICS Holding SA. Dr. Bevec received his undergraduate degree from the University of Vienna and his doctorate from Ludwig-Maximilians-Universität München.
Eerdere bekende functies van Habil Dorian Bevec
| Bedrijven | Functie | Einde |
|---|---|---|
| MINDMAZE THERAPEUTICS HOLDING SA | Corporate Officer/Principal | 31-12-2017 |
Sandoz Research Institute | Corporate Officer/Principal | - |
Axxima Pharmaceuticals AG
Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Researches and develops drugs | Corporate Officer/Principal | - |
THERAMetrics holding AG
THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology Discovers drugs for patients suffering from rare diseases | Oprichter | - |
Opleiding van Habil Dorian Bevec
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
University of Vienna
University of Vienna Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Axxima Pharmaceuticals AG
Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Researches and develops drugs | Commercial Services |
THERAMetrics holding AG
THERAMetrics holding AG Pharmaceuticals: MajorHealth Technology Discovers drugs for patients suffering from rare diseases | Health Technology |
Ludwig-Maximilians-Universität München
Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sandoz Research Institute | |
RELIEF THERAPEUTICS Holding SA
RELIEF THERAPEUTICS Holding SA Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of biopharmaceutical products for respiratory diseases | Health Technology |
















